secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-060702
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023
---------------------------------------------------------------------------

- Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.
- Collaboration revenue of $9.0M in FY 2022, down from $12.0M in FY 2021.
- Cash and equivalents $34.3M at Dec 31, 2022; raised $32.5M gross in Feb 2023 secondary offering.
- FDA assigned PDUFA date of July 23, 2023 for VP-102 NDA for molluscum contagiosum.
- VP-315 Phase 2 Part 2 dosing expected to begin in Q2 2023 for basal cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/0001193125-23-060702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/d474665d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-060702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer